Ultragenyx Pharmaceutical Prices Its $300M Underwritten Public Offering Of 8,333,334 Common Shares At $30/Share
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical has priced its $300M underwritten public offering of 8,333,334 common shares at $30/share. The company is also offering pre-funded warrants to purchase 1,666,722 shares of its common stock at a purchase price of $29.999 per pre-funded warrant.
October 19, 2023 | 6:07 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ultragenyx Pharmaceutical's public offering and pre-funded warrants could potentially dilute the value of existing shares, impacting the stock price.
The issuance of new shares or pre-funded warrants often leads to dilution of the value of existing shares. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100